tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
LENZ Therapeutics: Buy Rating Affirmed Amid Overreaction to Isolated Adverse Event
PremiumRatingsLENZ Therapeutics: Buy Rating Affirmed Amid Overreaction to Isolated Adverse Event
28d ago
Lenz Therapeutics confirms recent adverse event submitted to FDA
Premium
The Fly
Lenz Therapeutics confirms recent adverse event submitted to FDA
1M ago
LENZ Therapeutics Responds to FDA Adverse Event Report
Premium
Company Announcements
LENZ Therapeutics Responds to FDA Adverse Event Report
1M ago
LENZ Therapeutics Reports Strong Launch of VIZZ Eye Drop
PremiumCompany AnnouncementsLENZ Therapeutics Reports Strong Launch of VIZZ Eye Drop
2M ago
Lenz Therapeutics’ Earnings Call Highlights VIZZ Success
Premium
Company Announcements
Lenz Therapeutics’ Earnings Call Highlights VIZZ Success
2M ago
Promising Launch of LENZ Therapeutics’ VIZZ: A Buy Opportunity Amidst Strong Initial Performance and Market Enthusiasm
Premium
Ratings
Promising Launch of LENZ Therapeutics’ VIZZ: A Buy Opportunity Amidst Strong Initial Performance and Market Enthusiasm
2M ago
LENZ Therapeutics Raises $80M Through Stock Sale
PremiumCompany AnnouncementsLENZ Therapeutics Raises $80M Through Stock Sale
3M ago
Short Report: TeraWulf short interest at record high despite stock strength
Premium
The Fly
Short Report: TeraWulf short interest at record high despite stock strength
3M ago
LENZ Therapeutics: Buy Rating Affirmed Amid Successful Early Launch of Vizz and Promising Market Potential
Premium
Ratings
LENZ Therapeutics: Buy Rating Affirmed Amid Successful Early Launch of Vizz and Promising Market Potential
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100